Investing.com - Pardes Biosciences reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Pardes Biosciences announced earnings per share of $-0.400 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.440 on revenue of $0.00.
Pardes Biosciences 's are down 5.02% and is trading at $1.140 , still down 93.58% from its 52 week high of $17.76 set on Thursday, December 30, 2021.
Pardes Biosciences follows other major Healthcare sector earnings this month
Pardes Biosciences's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar